Elvina Almuradova/X
Jun 1, 2025, 09:04
Elvina Almuradova: ER Expression May Change Post-NAC – Should We Be Retesting?
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:
“ER Expression May Change Post-NAC – Should We Be Retesting?
New ASCO 2025 data (Abstract 529) show that >10% of patients with pretreatment ER-negative or ER-low breast cancer had increased ER expression in residual tumor tissue after neoadjuvant chemotherapy (NAC).
More than half underwent ER retesting.
Among those retested, 11% showed increased ER expression — opening the door for adjuvant endocrine therapy.
Particularly relevant for triple-negative and HER2+ cases treated as ER-negative pre-NAC.Key Message: If there’s residual disease post-NAC, consider ER retesting to individualize adjuvant therapy.”
Read OncoDaily’s Special Articles about ASCO 2025:
Highlights from ASCO 2025 Day 1
Highlights from ASCO 2025 Day 2
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 18:07
Jun 2, 2025, 18:00
Jun 2, 2025, 17:43
Jun 2, 2025, 17:18
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20